Avacta Group PLC (LS:A2ADP0) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new Ordinary Shares Update: £12.5M · GBX 68 a share · Zeus Capital Limited +2 Dealers: Zeus Capital Limited (lead), Beech Hill Securities, Inc., Strand Hanson Buyers: Richard Hughes (£500,000, 735,294 Subscription Shares); Patrick Vink (£75,000, 110,294 Subscription Shares); David Bryant (£50,000, 73,529 Subscription Shares); Mats Blom (£35,000, 51,470 Subscription Shares); Zeus Capital Limited (180,001 Ordinary Shares for £122,400.68) Insiders: Directors Richard Hughes, Patrick Vink, David Byrant and Mats Blom subscribed for 970,587 new Ordinary Shares, approximately £660,000 Use of proceeds: Extend cash runway into Q2 2027 and fund the company through multiple pipeline value inflection points | Oct 6, 2026 | US$16.59M |
| Private placement of placing Shares Closed: £16M raised · GBX 63 a share · Zeus Capital Limited Dealers: Zeus Capital Limited (lead) Use of proceeds: Working capital to progress R&D programs into 2H 2026, including the faridoxorubicin Phase 1b trial and planned FAP-EXd Phase Ia trial | Nov 3, 2025 | US$21.46M |
| Private placement of new ordinary shares Announced: £3.25M · GBX 50 a share · Zeus Capital Limited Dealers: Zeus Capital Limited (lead) Use of proceeds: To settle the October 2025 quarterly repayment of the unsecured convertible bond | Aug 29, 2025 | US$4.38M |
| Private placement of new ordinary shares Announced: £3.25M · GBX 30 a share · Zeus Capital Limited +1 Dealers: Zeus Capital Limited (lead), Turner Pope Investments (TPI) Limited Use of proceeds: To settle the July quarterly repayment of the unsecured convertible bond due on 21 July 2025 | Jul 17, 2025 | US$4.36M |